http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 13 Mar 2026 12:36:55 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Corporate+News/J%26J+reports+89%25+response+rate+in+bladder+cancer+drug+trial/26158292.html <p>Johnson & Johnson (NYSE: JNJ) announced results from a Phase 1 study of its investigational bladder cancer treatment Erda-iDRS, showing an 89% complete response rate in patients with intermediate-risk non-muscle-invasive bladder cancer.</p><p>The open-label, multicenter study evaluated the intravesical drug-releasing system containing erdafitinib in patients whose tumors harbor specific fibroblast growth factor receptor alterations. Results were presented at the European Association of Urology 2026 Annual Meeting.</p><p>The study included 62 patients with recurrent intermediate-risk disease and 26 patients with recurrent, high-risk non-muscle-invasive bladder cancer who had previously received Bacillus Calmette-Guérin therapy. The primary endpoint was safety, with secondary endpoints assessing complete response http://www.streetinsider.com/Corporate+News/J%26J+reports+89%25+response+rate+in+bladder+cancer+drug+trial/26158292.html Fri, 13 Mar 2026 12:36:55 -0400 JNJ http://www.streetinsider.com/FDA/J%26J+reports+89%25+response+rate+in+bladder+cancer+drug+trial/26158292.html <p>Johnson & Johnson (NYSE: JNJ) announced results from a Phase 1 study of its investigational bladder cancer treatment Erda-iDRS, showing an 89% complete response rate in patients with intermediate-risk non-muscle-invasive bladder cancer.</p><p>The open-label, multicenter study evaluated the intravesical drug-releasing system containing erdafitinib in patients whose tumors harbor specific fibroblast growth factor receptor alterations. Results were presented at the European Association of Urology 2026 Annual Meeting.</p><p>The study included 62 patients with recurrent intermediate-risk disease and 26 patients with recurrent, high-risk non-muscle-invasive bladder cancer who had previously received Bacillus Calmette-Guérin therapy. The primary endpoint was safety, with secondary endpoints assessing complete response http://www.streetinsider.com/FDA/J%26J+reports+89%25+response+rate+in+bladder+cancer+drug+trial/26158292.html Fri, 13 Mar 2026 12:36:55 -0400 JNJ http://www.streetinsider.com/Press+Releases/Johnson+%26amp%3B+Johnson+highlights+promising+first-in-human+Erda-iDRS+%28formerly+TAR-210%29+results+in+intermediate-risk+non-muscle-invasive+bladder+cancer/26158288.html <div class="xn-content"> <ul type="disc"><li><i>Data presented at EAU 2026 show an 89 percent complete response rate in intermediate-risk disease with durable responses observed over 18 months and tolerable safety profile </i></li><li><i>Erda-iDRS has the potential to be the first targeted treatment for early–stage bladder cancer</i></li></ul><p><span class="legendSpanClass"><location value="LU/us.nj.rartan" idsrc="xmltag.org" >RARITAN, N.J.</location></span>, <span class="legendSpanClass"><chron>March 13, 2026</chron></span> /PRNewswire/ -- Johnson &amp; Johnson (NYSE:JNJ) today announced results from an open-label, multicenter Phase 1 study evaluating an investigational intravesical drug-releasing system with erdafitinib (Erda-iDRS) in patients with intermediate-risk and high-risk non–muscle-invasive bladder cancer (NMIBC) whose tumors harbor select fibroblast growth factor receptor (<i>FGFR</i>) alterations. The study met its primary safety http://www.streetinsider.com/Press+Releases/Johnson+%26amp%3B+Johnson+highlights+promising+first-in-human+Erda-iDRS+%28formerly+TAR-210%29+results+in+intermediate-risk+non-muscle-invasive+bladder+cancer/26158288.html Fri, 13 Mar 2026 12:35:00 -0400 A.08001773 A.50100323 JNJ O.00000295 O.00042037 O.00160376 http://www.streetinsider.com/Press+Releases/Johnson+%26amp%3B+Johnson+highlights+promising+first-in-human+Erda-iDRS+%28formerly+TAR-210%29+results+in+intermediate-risk+non-muscle-invasive+bladder+cancer/26158288.html <div class="xn-content"> <ul type="disc"><li><i>Data presented at EAU 2026 show an 89 percent complete response rate in intermediate-risk disease with durable responses observed over 18 months and tolerable safety profile </i></li><li><i>Erda-iDRS has the potential to be the first targeted treatment for early–stage bladder cancer</i></li></ul><p><span class="legendSpanClass"><location value="LU/us.nj.rartan" idsrc="xmltag.org" >RARITAN, N.J.</location></span>, <span class="legendSpanClass"><chron>March 13, 2026</chron></span> /PRNewswire/ -- Johnson &amp; Johnson (NYSE:JNJ) today announced results from an open-label, multicenter Phase 1 study evaluating an investigational intravesical drug-releasing system with erdafitinib (Erda-iDRS) in patients with intermediate-risk and high-risk non–muscle-invasive bladder cancer (NMIBC) whose tumors harbor select fibroblast growth factor receptor (<i>FGFR</i>) alterations. The study met its primary safety http://www.streetinsider.com/Press+Releases/Johnson+%26amp%3B+Johnson+highlights+promising+first-in-human+Erda-iDRS+%28formerly+TAR-210%29+results+in+intermediate-risk+non-muscle-invasive+bladder+cancer/26158288.html Fri, 13 Mar 2026 12:35:00 -0400 A.08001773 A.50100323 JNJ O.00000295 O.00042037 O.00160376 http://www.streetinsider.com/Press+Releases/Johnson+%26amp%3B+Johnson+highlights+promising+first-in-human+Erda-iDRS+%28formerly+TAR-210%29+results+in+intermediate-risk+non-muscle-invasive+bladder+cancer/26158288.html <div class="xn-content"> <ul type="disc"><li><i>Data presented at EAU 2026 show an 89 percent complete response rate in intermediate-risk disease with durable responses observed over 18 months and tolerable safety profile </i></li><li><i>Erda-iDRS has the potential to be the first targeted treatment for early–stage bladder cancer</i></li></ul><p><span class="legendSpanClass"><location value="LU/us.nj.rartan" idsrc="xmltag.org" >RARITAN, N.J.</location></span>, <span class="legendSpanClass"><chron>March 13, 2026</chron></span> /PRNewswire/ -- Johnson &amp; Johnson (NYSE:JNJ) today announced results from an open-label, multicenter Phase 1 study evaluating an investigational intravesical drug-releasing system with erdafitinib (Erda-iDRS) in patients with intermediate-risk and high-risk non–muscle-invasive bladder cancer (NMIBC) whose tumors harbor select fibroblast growth factor receptor (<i>FGFR</i>) alterations. The study met its primary safety http://www.streetinsider.com/Press+Releases/Johnson+%26amp%3B+Johnson+highlights+promising+first-in-human+Erda-iDRS+%28formerly+TAR-210%29+results+in+intermediate-risk+non-muscle-invasive+bladder+cancer/26158288.html Fri, 13 Mar 2026 12:35:00 -0400 A.08001773 A.50100323 JNJ O.00000295 O.00042037 O.00160376 http://www.streetinsider.com/Press+Releases/Johnson+%26amp%3B+Johnson+highlights+promising+first-in-human+Erda-iDRS+%28formerly+TAR-210%29+results+in+intermediate-risk+non-muscle-invasive+bladder+cancer/26158288.html <div class="xn-content"> <ul type="disc"><li><i>Data presented at EAU 2026 show an 89 percent complete response rate in intermediate-risk disease with durable responses observed over 18 months and tolerable safety profile </i></li><li><i>Erda-iDRS has the potential to be the first targeted treatment for early–stage bladder cancer</i></li></ul><p><span class="legendSpanClass"><location value="LU/us.nj.rartan" idsrc="xmltag.org" >RARITAN, N.J.</location></span>, <span class="legendSpanClass"><chron>March 13, 2026</chron></span> /PRNewswire/ -- Johnson &amp; Johnson (NYSE:JNJ) today announced results from an open-label, multicenter Phase 1 study evaluating an investigational intravesical drug-releasing system with erdafitinib (Erda-iDRS) in patients with intermediate-risk and high-risk non–muscle-invasive bladder cancer (NMIBC) whose tumors harbor select fibroblast growth factor receptor (<i>FGFR</i>) alterations. The study met its primary safety http://www.streetinsider.com/Press+Releases/Johnson+%26amp%3B+Johnson+highlights+promising+first-in-human+Erda-iDRS+%28formerly+TAR-210%29+results+in+intermediate-risk+non-muscle-invasive+bladder+cancer/26158288.html Fri, 13 Mar 2026 12:35:00 -0400 A.08001773 A.50100323 JNJ O.00000295 O.00042037 O.00160376 http://www.streetinsider.com/Press+Releases/Johnson+%26amp%3B+Johnson+highlights+promising+first-in-human+Erda-iDRS+%28formerly+TAR-210%29+results+in+intermediate-risk+non-muscle-invasive+bladder+cancer/26158288.html <div class="xn-content"> <ul type="disc"><li><i>Data presented at EAU 2026 show an 89 percent complete response rate in intermediate-risk disease with durable responses observed over 18 months and tolerable safety profile </i></li><li><i>Erda-iDRS has the potential to be the first targeted treatment for early–stage bladder cancer</i></li></ul><p><span class="legendSpanClass"><location value="LU/us.nj.rartan" idsrc="xmltag.org" >RARITAN, N.J.</location></span>, <span class="legendSpanClass"><chron>March 13, 2026</chron></span> /PRNewswire/ -- Johnson &amp; Johnson (NYSE:JNJ) today announced results from an open-label, multicenter Phase 1 study evaluating an investigational intravesical drug-releasing system with erdafitinib (Erda-iDRS) in patients with intermediate-risk and high-risk non–muscle-invasive bladder cancer (NMIBC) whose tumors harbor select fibroblast growth factor receptor (<i>FGFR</i>) alterations. The study met its primary safety http://www.streetinsider.com/Press+Releases/Johnson+%26amp%3B+Johnson+highlights+promising+first-in-human+Erda-iDRS+%28formerly+TAR-210%29+results+in+intermediate-risk+non-muscle-invasive+bladder+cancer/26158288.html Fri, 13 Mar 2026 12:35:00 -0400 A.08001773 A.50100323 JNJ O.00000295 O.00042037 O.00160376 http://www.streetinsider.com/Press+Releases/Johnson+%26amp%3B+Johnson+highlights+promising+first-in-human+Erda-iDRS+%28formerly+TAR-210%29+results+in+intermediate-risk+non-muscle-invasive+bladder+cancer/26158288.html <div class="xn-content"> <ul type="disc"><li><i>Data presented at EAU 2026 show an 89 percent complete response rate in intermediate-risk disease with durable responses observed over 18 months and tolerable safety profile </i></li><li><i>Erda-iDRS has the potential to be the first targeted treatment for early–stage bladder cancer</i></li></ul><p><span class="legendSpanClass"><location value="LU/us.nj.rartan" idsrc="xmltag.org" >RARITAN, N.J.</location></span>, <span class="legendSpanClass"><chron>March 13, 2026</chron></span> /PRNewswire/ -- Johnson &amp; Johnson (NYSE:JNJ) today announced results from an open-label, multicenter Phase 1 study evaluating an investigational intravesical drug-releasing system with erdafitinib (Erda-iDRS) in patients with intermediate-risk and high-risk non–muscle-invasive bladder cancer (NMIBC) whose tumors harbor select fibroblast growth factor receptor (<i>FGFR</i>) alterations. The study met its primary safety http://www.streetinsider.com/Press+Releases/Johnson+%26amp%3B+Johnson+highlights+promising+first-in-human+Erda-iDRS+%28formerly+TAR-210%29+results+in+intermediate-risk+non-muscle-invasive+bladder+cancer/26158288.html Fri, 13 Mar 2026 12:35:00 -0400 A.08001773 A.50100323 JNJ O.00000295 O.00042037 O.00160376 http://www.streetinsider.com/PRNewswire/Johnson+%26amp%3B+Johnson+highlights+promising+first-in-human+Erda-iDRS+%28formerly+TAR-210%29+results+in+intermediate-risk+non-muscle-invasive+bladder+cancer/26158288.html <div class="xn-content"> <ul type="disc"><li><i>Data presented at EAU 2026 show an 89 percent complete response rate in intermediate-risk disease with durable responses observed over 18 months and tolerable safety profile </i></li><li><i>Erda-iDRS has the potential to be the first targeted treatment for early–stage bladder cancer</i></li></ul><p><span class="legendSpanClass"><location value="LU/us.nj.rartan" idsrc="xmltag.org" >RARITAN, N.J.</location></span>, <span class="legendSpanClass"><chron>March 13, 2026</chron></span> /PRNewswire/ -- Johnson &amp; Johnson (NYSE:JNJ) today announced results from an open-label, multicenter Phase 1 study evaluating an investigational intravesical drug-releasing system with erdafitinib (Erda-iDRS) in patients with intermediate-risk and high-risk non–muscle-invasive bladder cancer (NMIBC) whose tumors harbor select fibroblast growth factor receptor (<i>FGFR</i>) alterations. The study met its primary safety http://www.streetinsider.com/PRNewswire/Johnson+%26amp%3B+Johnson+highlights+promising+first-in-human+Erda-iDRS+%28formerly+TAR-210%29+results+in+intermediate-risk+non-muscle-invasive+bladder+cancer/26158288.html Fri, 13 Mar 2026 12:35:00 -0400 A.08001773 A.50100323 JNJ O.00000295 O.00042037 O.00160376 http://www.streetinsider.com/PRNewswire/Johnson+%26amp%3B+Johnson+highlights+promising+first-in-human+Erda-iDRS+%28formerly+TAR-210%29+results+in+intermediate-risk+non-muscle-invasive+bladder+cancer/26158288.html <div class="xn-content"> <ul type="disc"><li><i>Data presented at EAU 2026 show an 89 percent complete response rate in intermediate-risk disease with durable responses observed over 18 months and tolerable safety profile </i></li><li><i>Erda-iDRS has the potential to be the first targeted treatment for early–stage bladder cancer</i></li></ul><p><span class="legendSpanClass"><location value="LU/us.nj.rartan" idsrc="xmltag.org" >RARITAN, N.J.</location></span>, <span class="legendSpanClass"><chron>March 13, 2026</chron></span> /PRNewswire/ -- Johnson &amp; Johnson (NYSE:JNJ) today announced results from an open-label, multicenter Phase 1 study evaluating an investigational intravesical drug-releasing system with erdafitinib (Erda-iDRS) in patients with intermediate-risk and high-risk non–muscle-invasive bladder cancer (NMIBC) whose tumors harbor select fibroblast growth factor receptor (<i>FGFR</i>) alterations. The study met its primary safety http://www.streetinsider.com/PRNewswire/Johnson+%26amp%3B+Johnson+highlights+promising+first-in-human+Erda-iDRS+%28formerly+TAR-210%29+results+in+intermediate-risk+non-muscle-invasive+bladder+cancer/26158288.html Fri, 13 Mar 2026 12:35:00 -0400 A.08001773 A.50100323 JNJ O.00000295 O.00042037 O.00160376 http://www.streetinsider.com/PRNewswire/Johnson+%26amp%3B+Johnson+highlights+promising+first-in-human+Erda-iDRS+%28formerly+TAR-210%29+results+in+intermediate-risk+non-muscle-invasive+bladder+cancer/26158288.html <div class="xn-content"> <ul type="disc"><li><i>Data presented at EAU 2026 show an 89 percent complete response rate in intermediate-risk disease with durable responses observed over 18 months and tolerable safety profile </i></li><li><i>Erda-iDRS has the potential to be the first targeted treatment for early–stage bladder cancer</i></li></ul><p><span class="legendSpanClass"><location value="LU/us.nj.rartan" idsrc="xmltag.org" >RARITAN, N.J.</location></span>, <span class="legendSpanClass"><chron>March 13, 2026</chron></span> /PRNewswire/ -- Johnson &amp; Johnson (NYSE:JNJ) today announced results from an open-label, multicenter Phase 1 study evaluating an investigational intravesical drug-releasing system with erdafitinib (Erda-iDRS) in patients with intermediate-risk and high-risk non–muscle-invasive bladder cancer (NMIBC) whose tumors harbor select fibroblast growth factor receptor (<i>FGFR</i>) alterations. The study met its primary safety http://www.streetinsider.com/PRNewswire/Johnson+%26amp%3B+Johnson+highlights+promising+first-in-human+Erda-iDRS+%28formerly+TAR-210%29+results+in+intermediate-risk+non-muscle-invasive+bladder+cancer/26158288.html Fri, 13 Mar 2026 12:35:00 -0400 A.08001773 A.50100323 JNJ O.00000295 O.00042037 O.00160376 http://www.streetinsider.com/PRNewswire/Johnson+%26amp%3B+Johnson+highlights+promising+first-in-human+Erda-iDRS+%28formerly+TAR-210%29+results+in+intermediate-risk+non-muscle-invasive+bladder+cancer/26158288.html <div class="xn-content"> <ul type="disc"><li><i>Data presented at EAU 2026 show an 89 percent complete response rate in intermediate-risk disease with durable responses observed over 18 months and tolerable safety profile </i></li><li><i>Erda-iDRS has the potential to be the first targeted treatment for early–stage bladder cancer</i></li></ul><p><span class="legendSpanClass"><location value="LU/us.nj.rartan" idsrc="xmltag.org" >RARITAN, N.J.</location></span>, <span class="legendSpanClass"><chron>March 13, 2026</chron></span> /PRNewswire/ -- Johnson &amp; Johnson (NYSE:JNJ) today announced results from an open-label, multicenter Phase 1 study evaluating an investigational intravesical drug-releasing system with erdafitinib (Erda-iDRS) in patients with intermediate-risk and high-risk non–muscle-invasive bladder cancer (NMIBC) whose tumors harbor select fibroblast growth factor receptor (<i>FGFR</i>) alterations. The study met its primary safety http://www.streetinsider.com/PRNewswire/Johnson+%26amp%3B+Johnson+highlights+promising+first-in-human+Erda-iDRS+%28formerly+TAR-210%29+results+in+intermediate-risk+non-muscle-invasive+bladder+cancer/26158288.html Fri, 13 Mar 2026 12:35:00 -0400 A.08001773 A.50100323 JNJ O.00000295 O.00042037 O.00160376 http://www.streetinsider.com/PRNewswire/Johnson+%26amp%3B+Johnson+highlights+promising+first-in-human+Erda-iDRS+%28formerly+TAR-210%29+results+in+intermediate-risk+non-muscle-invasive+bladder+cancer/26158288.html <div class="xn-content"> <ul type="disc"><li><i>Data presented at EAU 2026 show an 89 percent complete response rate in intermediate-risk disease with durable responses observed over 18 months and tolerable safety profile </i></li><li><i>Erda-iDRS has the potential to be the first targeted treatment for early–stage bladder cancer</i></li></ul><p><span class="legendSpanClass"><location value="LU/us.nj.rartan" idsrc="xmltag.org" >RARITAN, N.J.</location></span>, <span class="legendSpanClass"><chron>March 13, 2026</chron></span> /PRNewswire/ -- Johnson &amp; Johnson (NYSE:JNJ) today announced results from an open-label, multicenter Phase 1 study evaluating an investigational intravesical drug-releasing system with erdafitinib (Erda-iDRS) in patients with intermediate-risk and high-risk non–muscle-invasive bladder cancer (NMIBC) whose tumors harbor select fibroblast growth factor receptor (<i>FGFR</i>) alterations. The study met its primary safety http://www.streetinsider.com/PRNewswire/Johnson+%26amp%3B+Johnson+highlights+promising+first-in-human+Erda-iDRS+%28formerly+TAR-210%29+results+in+intermediate-risk+non-muscle-invasive+bladder+cancer/26158288.html Fri, 13 Mar 2026 12:35:00 -0400 A.08001773 A.50100323 JNJ O.00000295 O.00042037 O.00160376 http://www.streetinsider.com/PRNewswire/Johnson+%26amp%3B+Johnson+highlights+promising+first-in-human+Erda-iDRS+%28formerly+TAR-210%29+results+in+intermediate-risk+non-muscle-invasive+bladder+cancer/26158288.html <div class="xn-content"> <ul type="disc"><li><i>Data presented at EAU 2026 show an 89 percent complete response rate in intermediate-risk disease with durable responses observed over 18 months and tolerable safety profile </i></li><li><i>Erda-iDRS has the potential to be the first targeted treatment for early–stage bladder cancer</i></li></ul><p><span class="legendSpanClass"><location value="LU/us.nj.rartan" idsrc="xmltag.org" >RARITAN, N.J.</location></span>, <span class="legendSpanClass"><chron>March 13, 2026</chron></span> /PRNewswire/ -- Johnson &amp; Johnson (NYSE:JNJ) today announced results from an open-label, multicenter Phase 1 study evaluating an investigational intravesical drug-releasing system with erdafitinib (Erda-iDRS) in patients with intermediate-risk and high-risk non–muscle-invasive bladder cancer (NMIBC) whose tumors harbor select fibroblast growth factor receptor (<i>FGFR</i>) alterations. The study met its primary safety http://www.streetinsider.com/PRNewswire/Johnson+%26amp%3B+Johnson+highlights+promising+first-in-human+Erda-iDRS+%28formerly+TAR-210%29+results+in+intermediate-risk+non-muscle-invasive+bladder+cancer/26158288.html Fri, 13 Mar 2026 12:35:00 -0400 A.08001773 A.50100323 JNJ O.00000295 O.00042037 O.00160376 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++JOHNSON+%26amp%3B+JOHNSON+++++For%3A+Mar+04++Filed+by%3A+HEWSON+MARILLYN+A/26155269.html si-local-file:///var/storage/secattach/20260312/26155269.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++JOHNSON+%26amp%3B+JOHNSON+++++For%3A+Mar+04++Filed+by%3A+HEWSON+MARILLYN+A/26155269.html Thu, 12 Mar 2026 21:31:00 -0400 JNJ O.00000295 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++JOHNSON+%26amp%3B+JOHNSON+++++For%3A+Mar+04++Filed+by%3A+HEWSON+MARILLYN+A/26155269.html si-local-file:///var/storage/secattach/20260312/26155269.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++JOHNSON+%26amp%3B+JOHNSON+++++For%3A+Mar+04++Filed+by%3A+HEWSON+MARILLYN+A/26155269.html Thu, 12 Mar 2026 21:31:00 -0400 JNJ O.00000295 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++JOHNSON+%26amp%3B+JOHNSON+++++For%3A+Mar+10++Filed+by%3A+Pinto+Daniel+E/26155169.html si-local-file:///var/storage/secattach/20260312/26155169.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++JOHNSON+%26amp%3B+JOHNSON+++++For%3A+Mar+10++Filed+by%3A+Pinto+Daniel+E/26155169.html Thu, 12 Mar 2026 20:40:00 -0400 JNJ O.00000295 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++JOHNSON+%26amp%3B+JOHNSON+++++For%3A+Mar+10++Filed+by%3A+Pinto+Daniel+E/26155169.html si-local-file:///var/storage/secattach/20260312/26155169.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++JOHNSON+%26amp%3B+JOHNSON+++++For%3A+Mar+10++Filed+by%3A+Pinto+Daniel+E/26155169.html Thu, 12 Mar 2026 20:40:00 -0400 JNJ O.00000295 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++JOHNSON+%26amp%3B+JOHNSON+++++For%3A+Mar+10++Filed+by%3A+Woods+Eugene+A./26155163.html si-local-file:///var/storage/secattach/20260312/26155163.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++JOHNSON+%26amp%3B+JOHNSON+++++For%3A+Mar+10++Filed+by%3A+Woods+Eugene+A./26155163.html Thu, 12 Mar 2026 20:37:00 -0400 JNJ O.00000295 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++JOHNSON+%26amp%3B+JOHNSON+++++For%3A+Mar+10++Filed+by%3A+Woods+Eugene+A./26155163.html si-local-file:///var/storage/secattach/20260312/26155163.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++JOHNSON+%26amp%3B+JOHNSON+++++For%3A+Mar+10++Filed+by%3A+Woods+Eugene+A./26155163.html Thu, 12 Mar 2026 20:37:00 -0400 JNJ O.00000295 http://www.streetinsider.com/FDA/Johnson+%26+Johnson+receives+FDA+approval+for+TECNIS+PureSee+eye+lens/26149549.html <p>Johnson & Johnson (NYSE: JNJ) announced that the U.S. Food and Drug Administration has approved its TECNIS PureSee IOL, an extended depth of focus intraocular lens for cataract surgery. The company stated that 97% of patients in clinical trials reported no very bothersome visual disturbances with the device.</p> <p>The lens is designed to address both cataract-related vision loss and presbyopia, a condition where eyes gradually lose the ability to see objects clearly up close. Johnson & Johnson claims the TECNIS PureSee IOL is the first and only FDA-approved extended depth of focus IOL that maintains contrast sensitivity comparable to an aspheric http://www.streetinsider.com/FDA/Johnson+%26+Johnson+receives+FDA+approval+for+TECNIS+PureSee+eye+lens/26149549.html Thu, 12 Mar 2026 08:00:56 -0400 A.04300633 A.06822034 A.17568957 A.17597923 A.31913558 JNJ O.00000295 O.00848801 O.04889877 O.19986975 O.20026344 O.34380831 http://www.streetinsider.com/FDA/Johnson+%26+Johnson+receives+FDA+approval+for+TECNIS+PureSee+eye+lens/26149549.html <p>Johnson & Johnson (NYSE: JNJ) announced that the U.S. Food and Drug Administration has approved its TECNIS PureSee IOL, an extended depth of focus intraocular lens for cataract surgery. The company stated that 97% of patients in clinical trials reported no very bothersome visual disturbances with the device.</p> <p>The lens is designed to address both cataract-related vision loss and presbyopia, a condition where eyes gradually lose the ability to see objects clearly up close. Johnson & Johnson claims the TECNIS PureSee IOL is the first and only FDA-approved extended depth of focus IOL that maintains contrast sensitivity comparable to an aspheric http://www.streetinsider.com/FDA/Johnson+%26+Johnson+receives+FDA+approval+for+TECNIS+PureSee+eye+lens/26149549.html Thu, 12 Mar 2026 08:00:56 -0400 A.04300633 A.06822034 A.17568957 A.17597923 A.31913558 JNJ O.00000295 O.00848801 O.04889877 O.19986975 O.20026344 O.34380831 http://www.streetinsider.com/FDA/Johnson+%26+Johnson+receives+FDA+approval+for+TECNIS+PureSee+eye+lens/26149549.html <p>Johnson & Johnson (NYSE: JNJ) announced that the U.S. Food and Drug Administration has approved its TECNIS PureSee IOL, an extended depth of focus intraocular lens for cataract surgery. The company stated that 97% of patients in clinical trials reported no very bothersome visual disturbances with the device.</p> <p>The lens is designed to address both cataract-related vision loss and presbyopia, a condition where eyes gradually lose the ability to see objects clearly up close. Johnson & Johnson claims the TECNIS PureSee IOL is the first and only FDA-approved extended depth of focus IOL that maintains contrast sensitivity comparable to an aspheric http://www.streetinsider.com/FDA/Johnson+%26+Johnson+receives+FDA+approval+for+TECNIS+PureSee+eye+lens/26149549.html Thu, 12 Mar 2026 08:00:56 -0400 A.04300633 A.06822034 A.17568957 A.17597923 A.31913558 JNJ O.00000295 O.00848801 O.04889877 O.19986975 O.20026344 O.34380831 http://www.streetinsider.com/FDA/Johnson+%26+Johnson+receives+FDA+approval+for+TECNIS+PureSee+eye+lens/26149549.html <p>Johnson & Johnson (NYSE: JNJ) announced that the U.S. Food and Drug Administration has approved its TECNIS PureSee IOL, an extended depth of focus intraocular lens for cataract surgery. The company stated that 97% of patients in clinical trials reported no very bothersome visual disturbances with the device.</p> <p>The lens is designed to address both cataract-related vision loss and presbyopia, a condition where eyes gradually lose the ability to see objects clearly up close. Johnson & Johnson claims the TECNIS PureSee IOL is the first and only FDA-approved extended depth of focus IOL that maintains contrast sensitivity comparable to an aspheric http://www.streetinsider.com/FDA/Johnson+%26+Johnson+receives+FDA+approval+for+TECNIS+PureSee+eye+lens/26149549.html Thu, 12 Mar 2026 08:00:56 -0400 A.04300633 A.06822034 A.17568957 A.17597923 A.31913558 JNJ O.00000295 O.00848801 O.04889877 O.19986975 O.20026344 O.34380831 http://www.streetinsider.com/FDA/Johnson+%26+Johnson+receives+FDA+approval+for+TECNIS+PureSee+eye+lens/26149549.html <p>Johnson & Johnson (NYSE: JNJ) announced that the U.S. Food and Drug Administration has approved its TECNIS PureSee IOL, an extended depth of focus intraocular lens for cataract surgery. The company stated that 97% of patients in clinical trials reported no very bothersome visual disturbances with the device.</p> <p>The lens is designed to address both cataract-related vision loss and presbyopia, a condition where eyes gradually lose the ability to see objects clearly up close. Johnson & Johnson claims the TECNIS PureSee IOL is the first and only FDA-approved extended depth of focus IOL that maintains contrast sensitivity comparable to an aspheric http://www.streetinsider.com/FDA/Johnson+%26+Johnson+receives+FDA+approval+for+TECNIS+PureSee+eye+lens/26149549.html Thu, 12 Mar 2026 08:00:56 -0400 A.04300633 A.06822034 A.17568957 A.17597923 A.31913558 JNJ O.00000295 O.00848801 O.04889877 O.19986975 O.20026344 O.34380831